Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Branded Generics Market Size, Value And Growth Trajectory Through 2030
The branded generics market size has seen rapid expansion in recent years. It is forecast to rise from $393.5 billion in 2025 to $434.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.4%. The historical period’s growth can be attributed to factors such as patent expirations of key drugs, growing generic drug acceptance, rising healthcare expenditure, government support for generics, and the increasing prevalence of chronic diseases.
The branded generics market is projected to experience substantial expansion in the coming years, with its value anticipated to reach $653.17 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This projected increase during the forecast period is attributable to several factors, including the broadening of branded generics product lines, the integration of digital marketing within the pharmaceutical sector, a rise in collaborations with healthcare providers, the expansion of emerging markets, and continuous improvements in drug formulation technologies. Key developments expected during this timeframe encompass enhanced brand recognition among patients, the implementation of distinctive marketing approaches, an increase in prescription volumes for branded generics, a growing inclination among physicians towards these products, and the ongoing enlargement of emerging markets for generic medications.
Get A Free Sample Report With In-Depth Market Insights:
Branded Generics Market Demand Drivers Opening New Revenue Streams
The increasing prevalence of chronic diseases is expected to fuel the expansion of the branded generics market. These are long-term health conditions that, while often not curable, can be managed and controlled. The rise in chronic diseases stems from factors such as increased use of tobacco products, insufficient nutrition, physical inactivity, excessive alcohol consumption, among others. Customers worldwide show a greater preference for branded generics to address chronic ailments, largely due to their affordability compared to standard medications. For instance, in April 2025, information from the Centers for Disease Control and Prevention, a US-based federal agency, indicated that in 2023, around 76.4% of U.S. adults reported experiencing at least one of 12 specified chronic conditions, and 51.4% of U.S. adults reported having multiple chronic conditions. Thus, the escalating occurrence of chronic diseases is a significant driver for the growth of the branded generics market.
Branded Generics Market Segment Analysis Spotlighting Growth Areas
The branded generics market covered in this report is segmented –
1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs
2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration
3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications
Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues
3) By Hormones: Corticosteroids, Thyroid Hormones
4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers
5) By Lipid Lowering Drugs: Statins, Fibrates
6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics
8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs
9) By Other Drugs: Analgesics, Antibiotics, Antivirals
Branded Generics Market Trends Powering Strategic Industry Growth
Leading firms in branded generics are collaborating with pertinent entities to utilize shared resources and broaden their reach into fresh markets. As an illustration, in September 2024, Biocon Ltd., an India-based pharmaceutical company, formed a partnership with Tabuk Pharmaceuticals. Biocon will undertake the development and production of the GLP-1 products, guaranteeing premium biopharmaceuticals specifically designed for diabetes treatment. Tabuk Pharmaceuticals will possess the marketing authorization rights and oversee the registration, import, and promotion of these products throughout the Middle East, with a particular focus on Saudi Arabia. The agreement contains clauses for subsequent expansion into additional GLP products beyond the initial range, thereby facilitating a wider array of diabetes treatments. This collaboration seeks to provide distinct health solutions that improve patient well-being in Saudi Arabia and neighboring regions, consistent with both companies’ dedication to enhancing healthcare availability. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company, marketing both branded and generic pharmaceutical products.
Branded Generics Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.
View The Full Branded Generics Market Report:
Branded Generics Market Geographic Distribution And Regional Opportunities
North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model